Brain Stimulation Rapidly Improves Cognitive Deficits in Long-COVID
Scientists demonstrate the effectiveness of non-invasive brain microcurrent stimulation therapy in reducing vascular dysregulation with long-COVID, which reduced visual and cognitive impairment in two patients, published in <em>Restorative Neurology and Neuroscience</em>
“COVID infection can induce delayed cognitive impairments that are quite serious in some patients,” explained lead investigator Bernhard A. Sabel, PhD, Director, Institute of Medical Psychology, Medical Faculty, Otto-von-Guericke University of Magdeburg, Magdeburg, Germany. “Common symptoms include fatigue, shortness of breath, and cognitive dysfunction such as lower attention span and loss of short-term memory, all of which have a dramatic impact on everyday functioning. There is currently no effective treatment that improves visual and cognitive impairments resulting from COVID-19 in such a short time.”
Vascular problems throughout the retina and the brain are the probable cause of long-COVID-19 symptoms. Because patients report vision loss, these investigators hypothesized that NIBS treatment could help induce cognitive recovery. This assumption was based on prior success improving vision in most of their glaucoma patients using this treatment.
Two female long-COVID-19 patients were treated for 10 and 13 days, respectively, with alternating current stimulation of the eyes and brain for 45 minutes daily. Both had vision problems and severe cognitive impairments, which resulted in being unable to work or carry out daily tasks. While one patient (age 40) had been infected with COVID-19, the other (age 72) had developed symptoms following AstraZeneca vaccination. Before and after therapy, cognition was assessed subjectively by interview and visual fields were quantified using perimetry. One patient was also assessed with a cognitive test battery and with a retinal dynamic vascular analyzer (DVA), a surrogate marker of vascular dysregulation in the brain.
In both patients NIBS markedly improved cognition and partially reversed visual field loss within three to four days. The significant improvements in their cognitive abilities included less fatigue, better short-term memory, attention, and multitasking. Both were able to return to work. The observations of blood vessels in the eye confirmed that the improvement may be explained by recovery from blood vessel constriction, which is a possible source of visual and cognitive decline. Formal cognitive tests confirmed recovery of up to 40%–60% in cognitive subfunctions with perimetry results showing stable and visual field recovery even during follow-up. DVA showed that NIBS reduced vascular dysregulation by normalizing vessel dynamics (dilation/constriction), with particularly noticeable changes in the small venous and arterial microvessels.
The investigators propose that hypometabolic neurons are the probable biological cause of the neurological deficits manifested as long-COVID symptoms, and that NIBS reactivates these “silent” neurons by reoxygenation, which is the presumed basis of recovery.
“This study is important because about 20–30% of COVID-19 patients develop significant cognitive deficits long after the early symptoms of infection have subsided, and clinicians have had little to offer so far,” noted co-author Andreas Gonschorek, MD, from the BG Clinic, Neurocenter Hamburg, Germany. “But the risk is much higher in hospitalized COVID-19 patients, with about 60% experiencing cognitive decline within four months. They suffer often long-lasting impairment of speech production, learning, memory, and executive functions. And they can suffer abnormalities in mood such as depression, anhedonia, and lower stress resilience.”
“This is the first demonstration that cognitive impairment can be improved in such a brief period of time. We believe that our treatment could benefit patients with long-COVID worldwide to improve cognitive impairment,” concluded Professor Dr. Sabel. “Our results are compatible with our earlier proposal that residual neuronal reserves can be reactivated by behavioral training or NIBS, providing a biological substrate for restoration of central nervous system function in the eye and brain. While NIBS is now already being offered in the clinic, further clinical trials should be conducted to study the mechanisms of action in greater detail.”
NOTES FOR EDITORS
Full open access study: “Non-invasive brain microcurrent stimulation therapy of long-COVID-19 reduces vascular dysregulation and improves visual and cognitive impairment” by Bernhard A. Sabel, Wanshu Zhou, Frank Huber, Florentina Schmidt, Kornelia Sabel, Andreas Gonschorek, and Mirela Bilc (DOI: 10.3233/RNN-211249), published in Restorative Neurology and Neuroscience, Volume 39, Issue 6. The open access article is available at: content.iospress.com/articles/restorative-neurology-and-neuroscience/rnn211249.
Data used in the study were provided by the SAVIR Center clinic, Magdeburg (www.savir-center.com) and the BG Clinic, Neurocenter Hamburg, Germany.
Full text of the article is also available to credentialed journalists upon request. Contact Diana Murray (+1 718 640 5678 or email@example.com). Journalists wishing to reach the authors should contact Bernhard A. Sabel (firstname.lastname@example.org).
About Restorative Neurology and Neuroscience
An interdisciplinary journal under the editorial leadership of Bernhard Sabel, PhD, Restorative Neurology and Neuroscience publishes papers relating the plasticity and response of the nervous system to accidental or experimental injuries and their interventions, transplantation, neurodegenerative disorders and experimental strategies to improve regeneration or functional recovery and rehabilitation. Experimental and clinical research papers adopting fresh conceptual approaches are encouraged. The overriding criteria for publication are novelty, significant experimental or clinical relevance and interest to a multidisciplinary audience. The journal is published by IOS Press. iospress.com/journal/restorative-neurology-and-neuroscience
RNN Editorial Office
Institut für Medizinische Psychologie
Otto-v.-Guericke Universität Magdeburg
About IOS Press
IOS Press is an independent international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in biomedical and life sciences (including neurosciences, medical informatics, cancer research, rehabilitation) and physical sciences (including computer sciences, artificial intelligence, engineering). In addition, we offer specialized services that support scientific advancement. iospress.com